Approximately 40% of the 3 million annual pediatric magnetic resonance imaging (MRI) examinations in the United States are performed with intravenous administration of a gadolinium-based contrast agent (GBCA). 1 Contrastenhanced MRI provides critical clinical information that is often not apparent on unenhanced MRI or other imaging modalities. Notwithstanding their widespread use, studies demonstrating the unexpected accumulation of gadolinium within the neural tissues of adults following intravenous GBCA exposure have prompted ongoing investigations by the US Food and Drug Administration and European Medicines Agency regarding the safety and toxicity of these agents. 2, 3 Because these prior studies were limited to adults, the purpose of this study was to determine the extent of deposition in the GBCAexposed population and whether prior observations were related to age-dependent breakdown of the blood-brain barrier through study of a cohort of pediatric patients who received gadodiamide-enhanced MRI examinations.
Methods | In this single-center retrospective case-control study approved by the Mayo Clinic institutional review board, postmortem brain tissues of pediatric patients (younger than age 18 years) who died between 2000 and 2015, received at least 4 gadodiamide-enhanced MRI examinations (Omniscan, 287 mg/mL, 0.1 mmol/kg; GE Healthcare, gadodiamide-exposed group), and who underwent autopsy following antemortem consent were compared with pediatric patients who did not receive any gadolinium-enhanced MRI examinations during their lifetime (control group). All clinical and imaging data were extracted from our medical record. Tissue samples were harvested from formalin-fixed whole-brain specimens at neuroanatomic locations (dentate nucleus, pons, globus pallidus, and thalamus) previously shown to be associated with increased levels of gadolinium deposition in adults. 4 Hematoxylin-eosinstained and neurofilament immunostained microscope slides were prepared using standard techniques. Gadolinium quantification and localization within tissue samples were carried out using inductively coupled plasma mass spectrometry and transmission electron microscopy with energy dispersive spectroscopy, respectively, as previously described.
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Results | Three gadodiamide-exposed pediatric patients were compared with 3 GBCA-naive control pediatric patients (Table) . Elemental gadolinium was detected in all 4 neuroanatomic regions among gadodiamide-exposed patients; the highest concentrations were detected in the dentate nucleus or pons. Transmission electron microscopy with energy dispersive spectroscopy revealed prominent clusters of gadolinium deposits within the endothelium and scattered smaller foci within the neural interstitium within these patients, indicating either direct or indirect transit across the blood-brain barrier ( Figure A-B) . No gadolinium was detected by inductively coupled plasma mass spectrometry or transmission electron microscopy in control patients. No pathologic changes were observed in dentate tissues of control or gadodiamide-exposed patients (Figure C-E). Dentate tissue from patients 1 and 2 who received the highest cumulative doses of gadodiamide had mildly to severely gliotic regions with prominent axonal spheroids ( Figure F) . It is unclear whether these pathologic changes are associated with prior external beam radiation therapy or with gadodiamide exposure.
Discussion | Our findings confirm the presence of intracranial gadolinium deposits in pediatric patients with normal renal function following exposure to intravenous gadodiamide for MRI examinations. Although our data are limited by small sample size, the deposition appears to follow a dosedependent trend with preferential accumulation in the dentate and deep gray nuclei, similar to what has been described in the adult population. 4-6 Such confirmation indicates that this deposition occurs independently of patient age. To our knowledge, there has been no observed adverse clinical symptom associated with gadolinium tissue deposition; yet, caution is warranted because free lanthanides are known to be neurotoxic and potentially mutagenic. Compared with adults, developing pediatric brains are more susceptible to the neurotoxic effects of heavy metal exposure, and it is possible that such susceptibility could also extend to the lanthanide-rare earth metals. For these reasons, ongoing research into the toxicology of GBCA exposure coupled with more judicious use of gadolinium contrast in the pediatric population is essential. Cellular localization of gadolinium using transmission electron microscopy (TEM) on tissue samples stained with 0.2% lead citrate are shown for the dentate nuclei of control patient 1 (A) and gadodiamide-exposed patient 3 (B) at 10 000-fold magnification. X-ray spectra of a selected electron dense foci (black arrowheads) are shown in the inset of each respective panel on a selected electron dense foci; gadolinium peaks in the spectra are indicated by red color overlay. Light microscopy images of hematoxylin-eosin-stained dentate nuclei samples (original magnification × 100) are shown for control patient 1 (C) and gadodiamide-exposed patients 3 and 1 (D and E 
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Treatment of Opioid Use Disorder During Pregnancy and Cases of Neonatal Abstinence Syndrome
To the Editor During the last 2 decades, use of prescription opioids and heroin increased throughout the United States. As use of licit and illicit opioids grew among pregnant women, cases of neonatal abstinence syndrome (NAS) surged nearly 5-fold nationwide. 1 In their article, Brown et al 2 described the rapid rise of NAS diagnoses in Kentucky from 2008 to 2014, growing at a rate twice the national mean. The authors raised the concern that state and federal public health interventions implemented to combat opioid use disorder during the study period may not have been effective, given that rates of NAS did not decrease. Efforts to expand treatment options, including opioid agonist therapy for pregnant women with opioid use disorder with methadone and buprenorphine, may in fact increase the number of cases of NAS, but this should still be considered a treatment success. An important limitation of this study, which relies on infant hospital discharge records, is that there is no way to identify whether infants were exposed in utero to opioid treatment or to illicit opioids. Methadone and buprenorphine reduce cravings and decrease the stressful cycle of withdrawal and intoxication for the mother and fetus. Because of this, treatment of pregnant women with opioid use disorder with opioid agonist therapy has shown to have improved maternal outcomes (eg, reduction in overdose risk and reduction in relapse risk) and infant outcomes (eg, higher birth weights and longer gestation). 3, 4 The American College of Obstetrics and Gynecology and the American Academy of Pediatrics both published statements supporting the use of opioid agonist therapy during pregnancy. [3] [4] [5] National and state policies that increase maternal access and engagement in treatment should be promoted, even if it means a transient increase in cases of NAS. As treatment options for pregnant women become more available and the number of cases of NAS in Kentucky and across the country grow, additional research is needed to understand factors that predict the severity of NAS, to standardize infant treatment protocols, and to support and families affected by substance use including those in recovery. In Reply Schiff and Patrick bring up 3 related points regarding our prior work in neonatal abstinence syndrome (NAS) rates nationally and in Kentucky. 1 The first is a limitation of the study, which was omitted owing to space limitations but acknowledged through reference to a study by Patrick et al. 2 In using administrative data with International Classification of Diseases, Ninth Revision codes to identify NAS cases, the possibility of misclassifying licit or illicit maternal opioid use will always exist. 2 This limitation can be overcome by using more detailed clinical data or by combining data sources to include measures of maternal medication use that were not available
